NRAS mutation: A potential biomarker of clinical response to immune-based therapies in metastatic melanoma (MM).
Douglas Buckner Johnson
No relevant relationships to disclose
Christine Marie Lovly
No relevant relationships to disclose
Marisa Flavin
No relevant relationships to disclose
Gregory Dan Ayers
No relevant relationships to disclose
Zhiguo Zhao
No relevant relationships to disclose
Wade Thomas Iams
No relevant relationships to disclose
Anthony John Iafrate
No relevant relationships to disclose
Elizabeth Gates Berry
No relevant relationships to disclose
Charles R Terry
No relevant relationships to disclose
Ryan J. Sullivan
No relevant relationships to disclose
Richard D. Carvajal
Research Funding - Bristol-Myers Squibb
Jeffrey Alan Sosman
No relevant relationships to disclose